Coherus Oncology, Inc. 8-K

What Happened

• On February 4, 2026, Coherus Oncology, Inc. (CHRS) filed a Form 8-K (Item 8.01) announcing a clinical supply agreement with Janssen Research & Development, LLC.
• Under the agreement Janssen will provide pasritamig to Coherus so Coherus can sponsor a Phase 1b clinical study evaluating a combination of Coherus’s investigational anti-CCR8 antibody tagmokitug (CHS-114) with Janssen’s T‑cell engaging bispecific antibody pasritamig in patients with metastatic castration‑resistant prostate cancer (mCRPC).
• The filing does not disclose any financial terms.

Key Details

• Date of filing/announcement: February 4, 2026.
• Study: Phase 1b trial in mCRPC to evaluate tagmokitug (CHS-114) + pasritamig.
• Roles: Janssen supplies pasritamig; Coherus will be the trial sponsor.
• Rights: Each company retains all commercial rights to its own compound (as monotherapy or in combination).

Why It Matters

• The agreement formalizes a collaboration to test Coherus’s lead investigational agent in combination with a Janssen bispecific in a hard‑to‑treat cancer population (mCRPC), advancing Coherus’s clinical development program.
• Being the trial sponsor gives Coherus control over the study execution and data generation, while Janssen’s supply of pasritamig provides access to a partner agent without disclosed upfront payments.
• Investors should note there were no financial details disclosed in the 8-K; material financial or operational impacts would require further disclosure in future filings if applicable.